The First-Ever Vaccine For Celiac Disease Has Begun Phase 2 Trials

A vaccine that could enable people with celiac disease to safely consume gluten has begun phase 2 testing in the US, Australia, and New Zealand after more than a decade of development.

Results from several phase 1 trials previously showed that the immune system-modifying treatment, called Nexvax2, is safe and tolerable. The upcoming studies will evaluate its efficacy.

Nexvax2 reprograms T-cells so that they no longer attack certain amino acid sequences – peptides – within the proteins that constitute gluten by repeatedly exposing the body to modified forms of three of these peptides. (Gluten is not one molecule, but rather a composite compound made of several different energy and mineral-rich proteins that, alongside starch, are stored in grain seeds.) In about 80 to 90 percent of celiac cases, the patient’s inflammatory response to gluten – which leads to the destruction of the intestinal lining if gluten is consumed frequently – arises because they are carriers of the HLA-DQ2.5 gene. This gene creates a recognition protein that instructs T-cells to flag harmless gluten peptides as dangerous.

The vaccine will not work for individuals with non-HLA-DQ2.5-mediated gluten sensitivity.

Recommended For You

DFY Member

Done For You Membership Sites, Instantly Add Multiple Streams Of Recurring Income To Your Online Business By Giving Great (Done For You) Content Away!

LeadFunnelCloud Enterprise

Get this Cloud Based App That Creates INSTANT Done-For-You UNLIMITED Profitable Lead Funnels To Build A HUGE List,Drive Targeted Social Traffic and Affiliate Commissions In Just 60 Seconds

PixlyPro - Reseller 25 Licenses

Cutting edge software creates viral marketing campaigns across multiple platforms – slashing the cost of traffic to a few cents per clickNew technology integrates call to action with 6 remarketing platforms, Never seen before concept Cheap, targeted tra

“The initiation of our Nexvax2 Phase 2 trial is significant for patients who suffer from celiac disease, a condition affecting approximately 1% of the global population,” Leslie Williams, CEO of ImmusanT, the company behind Nexvax2, said in a statement earlier this year. “This trial is designed to demonstrate protection against inadvertent exposure to gluten, but the ultimate goal is to develop Nexvax2 as a treatment that will allow patients to return to an unrestricted diet.”

According to Dr Jason Tye-Din, a gastroenterologist at the Royal Melbourne Hospital and head of celiac research at the Walter and Eliza Hall Institute, the vaccine is expected to work for the majority of patients with the genetic form of celiac disease. Dr Tye-Din, who will lead the Australian portion of the trial, has been involved with Nexvax2 since the beginning. He and Dr Bob Anderson, now chief scientific officer for ImmusanT, led the team that first identified the immune-triggering peptides in 2003.

ImmusanT researchers hope to enroll 150 celiac patients across the three countries. Participants will receive 32 total injections of Nexvax2 or placebo, given at twice-weekly intervals, then undergo masked gluten food challenges (meaning they won’t know whether or not gluten is present in the food items). The company reported that the first patient joined the trial and began injections in late September. As of now, most of the 40 study sites are actively recruiting more participants or will begin to do so soon.  

“This trial is important in establishing clinical proof-of-concept for a treatment that would provide benefit beyond that of the gluten-free diet,” Dr Tye-Din stated. “The gluten-free diet is the only current treatment for celiac disease, but it is onerous, complex and not always effective. Even the most diligent patients can suffer the adverse effects of accidental exposure.”

“A successful therapy that can restore normal gluten tolerance would revolutionize celiac disease management,” he said in a different release.

Recommended For You

Vizully PLATINUM Lite

Vizully PLATINUM Edition Gets You BUYERS Hands-FREE With Your Unique Mini-Video Gifs and Moving Images On Social Networks For More Profits On Autopilot.

Bolt Publisher - Rebrandable Consultant License

This is a rebrandable version of Bolt Publisher you can sell to businesses.

Per the ImmusanT website, treatment with Nexvax2 will involve multiple doses to gradually acclimate T-cells to gluten peptides. During which time, the inflammation and tissue damage in the gut may heal, alleviating the disease’s symptoms. Ideally, the individual could then consume gluten in small amounts or freely without an immune response. Periodic boosters will be needed to maintain prolonged gluten tolerance.

Original Article : HERE ; This post was curated & posted using : RealSpecific

Thank you for taking the time to read our article.

If you enjoyed our content, we'd really appreciate some "love" with a share or two.

And ... Don't forget to have fun!

Recommended Products

Instant eCom Funnels LICENSE PRO

Done For You eCom Product Funnels In Less Than 60 Seconds! Perfect for dropshippers who want to avoid expensive Shopify fees!

Clickopia Silver Triple-Up (30,000 clicks/mo.) ** NOTICE - THIS UPGRADE REQUIRES CLICKOPIA SILVER **

Clickopia Silver Triple-Up Click Tracking Service - Monthly service with a one-time price. Upgrade to Track 450 links for up to 30,000 clicks per month.


IM Affiliate Funnel 2.0 - Affiliate Marketing Strategies To 5 Figure Promotions. Limited Time Special Offer.

Leave a Reply